- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04818242
Dexcom CGM in Long-term Care
Randomized Controlled Trial To Assess the Benefits of Dexcom Continuous Glucose Monitoring With Glucose Telemetry System for the Management of Diabetes in Long-term Care Setting: The CGM-GTS in Long-term Care
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Diabetes is prevalent in adults admitted to subacute rehab (SAR) and long-term care (LTC) skilled nursing care facilities.
Management of diabetes in these facilities is challenging due to number of older adults with higher prevalence of other diseases, functional disability, and altered nutritional intake, which increase the risk of hypoglycemia (low blood sugars).
Many Clinical guidelines recommend the use of insulin, as the preferred therapy for glycemic (sugar) control for most patients with type 2 diabetes (T2D). The use of insulin is effective in improving glycemic control, but associated with high rates of hypoglycemia in LTC residents with T2D. This high rate of hypoglycemia is concerning, because hypoglycemia has been associated with many complications and mortality.
The bedside capillary point of care (POC) glucose monitoring is the standard of care to assess glycemic control in the hospital and in LTC facilities. POC testing is usually performed before meals and at bedtime. Continuous Glucose Monitoring (CGM) measures glucose every 5-15 minutes, thus provides a more complete glycemic profile during 24-hours when compared to POC testing.
The investigators propose to conduct a randomized controlled trial to determine whether the use of Dexcom CGM with Glucose Telemetry System (CGM-GTS) with hypoglycemia alarm compared to standard of care using capillary POC testing, will facilitate diabetes treatment and reduce the risk of hypoglycemia in patients with T2D in LTC facilities. Participants in the standard of care group will also wear a CGM (blinded one).
Potential Participants will be identified from electronic medical records and enrolled during admission to subacute rehabilitation (SAR)and long-term care (LTC) skilled nursing care facilities and will be followed up for up to sixty (60) days or discharge (whichever comes sooner). Subjects will be compensated for their participation.
The results of this study have great potential to impact and facilitate care and to change current clinical guidelines in the management of older adults with diabetes in SAR and LTC facilities.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Saumeth Cardona, MD
- Phone Number: 404-251-8957
- Email: scardon@emory.edu
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30329
- Recruiting
- A.G. Rhodes
-
Contact:
- Emmelin Moreno
- Phone Number: 404-686-7397
- Email: emmelin.marie.moreno@emory.edu
-
Atlanta, Georgia, United States, 30329
- Recruiting
- Emory Wesley Woods Hospital
-
Contact:
- Emmelin Moreno
- Phone Number: 404-686-7397
- Email: emmelin.marie.moreno@emory.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males and females admitted to subacute and long-term skilled nursing care facilities.
- Known history of T2D treated with insulin (glargine, detemir, degludec, NPH, premixed insulin) or sliding scale regular insulin) or insulin secretagogues (sulfonylureas, repaglinide, nateglinide) with or without additional oral antidiabetic agents (alpha-glucosidase inhibitors, thiazolidinedione, SGLT2- inhibitors, DPP4-inhibitors), short- and long-acting GLP1-RA (exenatide, liraglutide, dulaglutide, semaglutide).
- Patients with an expected LTC length-of-stay > 1 week.
Exclusion Criteria:
- Patients expected to require MRI procedures during admission.
- Patients with clinically relevant hepatic disease (diagnosed liver cirrhosis and portal hypertension), corticosteroid therapy, end-stage renal disease (dialysis), or anasarca (massive peripheral edema).
- Female subjects who are pregnant or breast-feeding at time of enrollment into the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: POC testing with Blinded CGM Group (Standard of Care Group)
Patients in the standard of care group will wear a blinded CGM and receive POC testing before meals and bedtime, with providers adjusting oral agents or insulin dose based on POC results.
|
Point of Care (POC) testing before meals and bedtime (standard of care).
For the control group, participants will also get a CGM sensor (blinded CGM).
CGM alarms are turned off, however if the POC is found to be between <80 mg/dl by POC, 15 grams of carbohydrates will be given as a preventive measurement for hypoglycemia (standard of care).
Other Names:
|
Experimental: Dexcom CGM with Glucose Telemetry System Group (CGM-GTS Group)
Patients in the intervention CGM group will have a single daily fasting POC testing and will wear a real-time Dexcom G6 with GTS, and providers will adjust oral or insulin therapy based on CGM-GTS profile information.
|
CGM sensor will be placed after consent.
Glucose values obtained from the CGM sensor will be sent to the CGM transmitter by Bluetooth technology and DEXCOM Share2 software application to a smart phone that serves as an intermediate-transmitting (routing) device.
Glucose values from the smart phone will be transmitted wirelessly to a table computer (I-Pad) using the DEXCOM Follow application.
Information on the CGM will activate an alarm in case of hypoglycemia or hyperglycemia events.
Hypoglycemia alarm will be set to < 85 mg/dl (for prevention for low blood glucose levels).
Nursing staff will be instructed to provide 15 grams of carbohydrates in response to a hypoglycemia alarm.The hyperglycemia alarm will be set at 300 mg/dl.
If this occurs, the nursing staff will assess clinical status and perform a POC glucose testing to confirm glucose values.
If BG > 300 mg/dl, nursing staff will communicate the high glucose value to the primary care team.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of events of Hypoglycemia <70 mg/dl
Time Frame: During hospitalization (up to 60 days of admission)
|
Number of events of Hypoglycemia <70 mg/dl between POC testing group and CGM-GTS group (safety outcome)
|
During hospitalization (up to 60 days of admission)
|
Number of events of clinically significant hypoglycemia <54 mg/dl
Time Frame: During hospitalization (up to 60 days of admission)
|
Number of events of clinically significant hypoglycemia <54 mg/dl between POC testing group and CGM-GTS group (safety outcome)
|
During hospitalization (up to 60 days of admission)
|
Time in range (TIR) between 80-180 mg/dl
Time Frame: During hospitalization (up to 60 days of admission)
|
Glycemic control will be measured by time in range (TIR) between 80-180 mg/dl during admission (efficacy outcome)
|
During hospitalization (up to 60 days of admission)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of events of nocturnal hypoglycemia < 70 mg/dL and <54 mg/dL between POC testing group and CGM-GTS group
Time Frame: During hospitalization (up to 60 days of admission)
|
Number of events of nocturnal hypoglycemic events for BGs < 70 mg/dl and <54 mg/dL will be recorded between 22:00 and 06:00
|
During hospitalization (up to 60 days of admission)
|
Number of hypoglycemia events
Time Frame: During hospitalization (up to 60 days of admission)
|
Number of events of hypoglycemia <70 mg/dl and <54 mg/dl between POC testing group and CGM-GTS group
|
During hospitalization (up to 60 days of admission)
|
Time in hypoglycemia (<70 mg/dl) in minutes
Time Frame: During hospitalization (up to 60 days of admission)
|
Time in hypoglycemia (<70 mg/dl) in minutes between POC testing group and CGM-GTS group
|
During hospitalization (up to 60 days of admission)
|
Time in hyperglycemia (>240 mg/dl) in minutes
Time Frame: During hospitalization (up to 60 days of admission)
|
Time in hyperglycemia (>240 mg/dl) in minutes between POC testing group and CGM-GTS group
|
During hospitalization (up to 60 days of admission)
|
Number of prolonged hypoglycemia > 1 and 2 hours by CGM
Time Frame: During hospitalization (up to 60 days of admission)
|
Number of participants with prolonged hypoglycemia > 1 and 2 hours by CGM between POC testing group and CGM-GTS group
|
During hospitalization (up to 60 days of admission)
|
Number of hypoglycemia events during the day and night
Time Frame: During hospitalization (up to 60 days of admission)
|
Number of hypoglycemia events during the day and night between POC testing group and CGM-GTS group
|
During hospitalization (up to 60 days of admission)
|
Time in hypoglycemia (minutes)
Time Frame: During hospitalization (up to 60 days of admission)
|
Time in hypoglycemia (minutes) during the day and night between POC testing group and CGM-GTS group
|
During hospitalization (up to 60 days of admission)
|
Number of events of hyperglycemia > 240 mg/dl
Time Frame: During hospitalization (up to 60 days of admission)
|
Number of events of hyperglycemia > 240 mg/dl during the day and night between POC testing group and CGM-GTS group
|
During hospitalization (up to 60 days of admission)
|
Time in hyperglycemia > 240 mg/dl (minutes)
Time Frame: During hospitalization (up to 60 days of admission)
|
Time in hyperglycemia > 240 mg/dl (minutes) during the day and night
|
During hospitalization (up to 60 days of admission)
|
Percentage of BG readings within target BG of 70 and 180 mg/dl
Time Frame: During hospitalization (up to 60 days of admission)
|
Percentage of BG readings within target BG of 70 and 180 mg/dl of all BG readings
|
During hospitalization (up to 60 days of admission)
|
Glycemic variability calculated by Mean amplitude of glycemic excursions (MAGE)
Time Frame: During hospitalization (up to 60 days of admission)
|
Mean amplitude of glycemic excursions (MAGE), together with mean and SD, is the parameter for assessing glycemic variability and is calculated based on the arithmetic mean of differences between consecutive peaks and nadirs of differences greater than one SD of mean glycemia.
It is designated to assess major glucose swings and exclude minor ones.
|
During hospitalization (up to 60 days of admission)
|
Number of sensor removed
Time Frame: During hospitalization (up to 60 days of admission)
|
Number of sensor removed for procedures/imaging, sensors failures, sensors dislodgments
|
During hospitalization (up to 60 days of admission)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Guillermo Umpierrez, Emory University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00001529
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
AstraZenecaRecruiting
Clinical Trials on POC BG + Blinded CGM
-
Emory UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedType 2 Diabetes | End-Stage Renal DiseaseUnited States
-
University Hospital PadovaBoston Children's Hospital; University of PadovaCompletedInfant, Very Low Birth Weight | Neonatal HypoglycemiaUnited States, Italy
-
Jaeb Center for Health ResearchDexCom, Inc.Completed
-
University Hospital PadovaUniversity of PadovaRecruitingInfant Development | Neurodevelopmental Abnormality | Hypoglycemia NeonatalItaly
-
Woman'sDexCom, Inc.RecruitingPostpartum Gestational Diabetes MellitusUnited States
-
Woman'sDexCom, Inc.CompletedGestational Diabetes Mellitus in PregnancyUnited States
-
Palo Alto Medical FoundationEmory University; Abbott Diabetes CareRecruiting
-
University of Maryland, BaltimoreDexCom, Inc.CompletedDiabetes MellitusUnited States